[Preliminary study of the safety and immunogenicity of the attenuated VD47/25 strain of camelpoxvirus].

The safety and immunogenicity of the attenuated VD47/25 strain of camelpoxvirus were tested on 30 camel calves in Mauritania. Post-inoculation clinical symptoms were absent during the 40 days of observation. Serum samples collected during this period showed low levels of neutralizing antibodies (1/4-1/16). In vivo titration of a virulent strain of camelpoxvirus in vaccinated camels and control animals enabled the calculation of the PD50 (50% protective dose) which contained the equivalent of 10(3.7) TCID50 (50% cell culture infective dose). Other studies are still required to determine the dose of this vaccine needed to protect 95% of vaccinated animals.